BR Biopharma, Inc. (NASDAQ:BRBI – Get Free Report) saw a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 3,543 shares, a growth of 50.9% from the July 30th total of 2,348 shares. Based on an average trading volume of 742 shares, the days-to-cover ratio is presently 4.8 days. Currently, 0.0% of the company’s shares are short sold.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, BR Biopharma presently has a consensus rating of “Sell”.
View Our Latest Analysis on BR Biopharma
Institutional Trading of BR Biopharma
BR Biopharma Trading Up 8.4%
NASDAQ BRBI traded up $0.83 during trading hours on Tuesday, hitting $10.75. 107 shares of the company’s stock were exchanged, compared to its average volume of 958. The firm has a 50-day moving average of $10.84. BR Biopharma has a 1-year low of $9.09 and a 1-year high of $67.01. The stock has a market cap of $126.96 million and a price-to-earnings ratio of 133.81.
BR Biopharma (NASDAQ:BRBI – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.09 earnings per share (EPS) for the quarter. The business had revenue of $25.13 million during the quarter.
BR Biopharma Cuts Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 4th. Stockholders of record on Monday, August 17th will be issued a dividend of $0.1415 per share. The ex-dividend date is Monday, August 17th. This represents a $0.57 annualized dividend and a dividend yield of 5.3%. BR Biopharma’s dividend payout ratio is currently 625.00%.
BR Biopharma Company Profile
BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.
See Also
- Five stocks we like better than BR Biopharma
- Palantir’s Sovereign AI Pitch Tests Microsoft’s Cloud-First AI Bet
- Salesforce Looks Overbought, But the Rally May Be Far From Over
- Radar Anomaly: Draganfly’s Options Surge Signals Strategy Shift
- Boarding Call: EHang Secures First-Mover Altitude
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
